Clinical Trial

Verona Coronary Physiology Interventional Registry

Study acronym: VR-CP
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 22, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The Verona Coronary Physiology Interventional Registry (VR-CP) is an observational study that collects information on patients with suspected coronary artery disease who underwent coronary angiography with a functional assessment of coronary stenoses. These functional tests include fractional flow reserve (FFR) or angiography-derived FFR, which help physicians understand whether a narrowing in the coronary arteries is likely to reduce blood flow to the heart. The main goal of the study is to investigate whether the functional severity of coronary lesions is associated with future cardiovascular events, such as heart attack, the need for repeat procedures, or cardiovascular death. Additional objectives are to compare invasive FFR with angiography-derived FFR, to evaluate how these values relate to angina symptoms, and to analyze differences between patients treated conservatively with medications and those treated with coronary interventions. The study is retrospective and single-center, including approximately 1,000 patients who underwent coronary physiology testing between 2010 and 2024 at the University Hospital of Verona. Follow-up information is obtained through review of medical records, outpatient visits, or telephone contacts, and patients will be followed for up to 10 years. By combining detailed coronary physiology data with long-term clinical outcomes, this registry aims to improve understanding of which patients are at higher risk and to guide future strategies for the diagnosis and treatment of coronary artery disease.
Trial Details
NCT Number NCT07186582
Lead Sponsor Azienda Ospedaliera Universitaria Integrata Verona
Conditions Coronary Artery Disease, Ischemic Heart Disease (IHD), Coronary Heart Disease (CHD)
Enrollment 1,000 participants
Start Date 2025-07-14
Primary Completion 2025-12-31 (estimated)
Study Completion 2034-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-22